John Clarke steps down as non-executive chairman of Futura Medical

Futura Medical, a pharmaceutical company developing a portfolio of products based on its proprietary, transdermal DermaSys drug delivery technology focused on sexual health, has announced that non-executive chairman, John Clarke has stepped down and is succeeded by existing non-executive board member, Jeff Needham.

Clarke joined Futura on 1st November 2011 and has been part of driving the company’s strategy and success in securing commercial partnerships. His departure is part of a planned transition with Independent non-executive director, Needham succeeding Clarke as chairman. Needham has been a non-executive director of the company since October 2021. A search for a new non-executive director is underway and an announcement will be made in due course. The company continues its progress in broadening the distribution and availability of MED3000 across different markets, worldwide.

James Barder, chief executive officer of Futura, said: “John has been an outstanding leader and has been instrumental in shaping the growth of Futura since his appointment. On behalf of the board and the Futura team I would like to thank him for his significant contributions and critical guidance and leadership. We wish John all the best for the future and in his new roles elsewhere. As the commercialisation of MED3000 continues to gather pace in the US and globally, we are fortunate to have a natural successor on the board. Jeff’s extensive experience and expertise with the consumer healthcare products industry, in particular in the US market, will be invaluable as Futura enters an exciting new chapter in its development.”

John Clarke, departing chairman of Futura, commented: “Following yesterday’s announcement of the company’s US collaboration with global leading consumer healthcare company, Haleon, and as the company enters its next stage of growth, it is the appropriate time for me, after twelve years to move on. It has been a privilege to work with the Futura team, seeing transformational progress, growth and execution. Achieving FDA approval for our lead product MED3000 was a critical focus for me as chairman, significantly de-risking MED3000 and allowing the company to negotiate a US commercialisation deal that would make MED3000 available to consumers in the largest ED market worldwide. It is now a pleasure to pass the baton to Jeff who I trust to continue to lead the business on its next stage of growth and innovation."